A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Sponsor: Incyte Corporation
Listed as NCT03607487, this PHASE2 trial focuses on Hidradenitis Suppurativa and remains completed. Sponsored by Incyte Corporation, it has been updated 13 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Nov 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2020 — Oct 2020 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Feb 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus, Denmark , Barrie, Canada , Bochum, Germany , Drummondville, Canada , Fredericton, Canada , London, Canada , Lübeck, Germany , Markham, Canada , Richmond Hill, Canada , Roskilde, Denmark and 3 more locations